Novo Nordisk A/S (NYSE:NVO) Trading Down 0.4%

Novo Nordisk A/S (NYSE:NVO)’s share price traded down 0.4% on Wednesday . The stock traded as low as $121.79 and last traded at $123.45. 3,044,113 shares were traded during trading, a decline of 15% from the average session volume of 3,581,832 shares. The stock had previously closed at $123.90.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, April 1st. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Down 0.4 %

The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The stock has a market cap of $553.99 billion, a P/E ratio of 45.72, a P/E/G ratio of 2.06 and a beta of 0.41. The stock’s fifty day simple moving average is $126.16 and its 200-day simple moving average is $110.32.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.33 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were given a $0.664 dividend. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is 48.89%.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently modified their holdings of the company. Roundview Capital LLC boosted its stake in Novo Nordisk A/S by 0.6% during the first quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock worth $2,088,000 after acquiring an additional 106 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Novo Nordisk A/S by 45.4% in the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after buying an additional 1,571,747 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Novo Nordisk A/S by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock valued at $82,131,000 after buying an additional 6,903 shares in the last quarter. Blair William & Co. IL lifted its stake in shares of Novo Nordisk A/S by 12.7% in the first quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock valued at $2,136,000 after buying an additional 2,194 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in shares of Novo Nordisk A/S by 17.5% in the first quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock valued at $11,913,000 after buying an additional 15,996 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.